Navigation Links
InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
Date:5/28/2009

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT.

Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of INT131 to safely and effectively address insulin resistance in a presentation entitled "INT131: Significantly Lowers Glucose Without Typical Thiazolidinedione (TZD) Side Effects in Patients with Type 2 Diabetes."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Purposefully designed as a SPPARM, INT131 selectively modulates PPAR-gamma, thereby allowing the retention of the clinically proven anti-diabetic efficacy of PPAR gamma activation, while mitigating or eliminating the well recognized side effects of TZD full PPAR gamma agonists rosiglitazone and pioglitazone (Avandia(R) and Actos(R) respectively).

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.


'/>"/>
SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
4. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
5. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
10. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
11. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... DIEGO , 23 janvier 2017  ResMed (NYSE : ... Haven , Floride) ont annoncé aujourd,hui qu,ils se sont ... litiges existants entre les parties. BMC et 3B seront ... paiements de droits à ResMed, et ResMed effectuera le ... 3B pour clore le litige de Floride entre les ...
(Date:1/23/2017)... InDex Pharmaceuticals Holding AB (publ) today announced that the company ... Crohn,s and Colitis Organisation (ECCO). The ECCO congress is the largest ... disease (IBD). The congress is held in Barcelona, Spain ... ... selected to present data at the largest IBD congress in the ...
(Date:1/21/2017)... (NYSE: RMD ), BMC ( Beijing, China ... today announced they have agreed on a global settlement of all ... sell their existing products in exchange for royalty payments to ResMed, ... close the Florida litigation between the two ... wrongdoing by any party. The five-year agreement between ...
Breaking Medicine Technology:
(Date:1/22/2017)... (PRWEB) , ... January 22, 2017 , ... Zifam Pinnacle, ... across the world, recently met with big-name retail buyers at the January ECRM Trade ... of efficacy and uses the utmost safety standards in all of its creations to ...
(Date:1/21/2017)... ... ... perfect set of tools for video editors that want to create the illusion of rack ... of Pixel Film Studios. , Video editors using ProDOF can add realistic depth of ... from one area into the next. ProDOF comes with 0.5 second, 1.0 second, 1.5 ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is ... at 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam ... rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema ...
(Date:1/20/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has posted a new publication ... this generation is a time like no other and society needs to understand the only ... he does not want to sound like an old bible beater because religion has a ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an ... lives, recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting ... its large range of supplements that keep the body functioning at its peak ...
Breaking Medicine News(10 mins):